|
1）Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J Clin Microbiol. 1986; 24: 157-60
|
|
|
|
2）Mizuno D, Ide-Kurihara M, Ichinomiya T, et al. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol. 2006; 176: 1122-30
|
|
|
|
|
|
3）Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356: 685-96
|
|
|
|
|
4）Esposito S, Montinaro V, Groppali E, et al. Live attenuated intranasal influenza vaccine. Hum Vaccine Immunother. 2012; 8: 17-20
|
|
|
|
|
|
5）Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005; 11: 45-53
|
|
|
|
|
|
6）木戸 博，水野 大，木本貴士．粘膜免疫機能とインフルエンザ感染．小児内科．2010; 42: 1541-5
|
|
|
|
|
7）Fujimoto C, Takeda N, Matsunaga A, et al. Induction and maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG levels after influenza infection in adults. Influenza Other Respi Viruses. 2012; 6: 396-403
|
|
|
|
|
|
8）Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine. 2000; 18: 957-1030
|
|
|
|
|
|
9）Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005; 366: 1165-74
|
|
|
|
|
|
10）Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol. 2003; 13: 293-310
|
|
|
|
|
|
11）Kimoto T, Mizuno D, Takei T, et al. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses. Influenza Other Respir Viruses. 2013; 7: 1218-26
|
|
|
|
|
|
12）Sawabuchi T, Suzuki S, Iwase K, et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology. 2009; 14: 1173-9
|
|
|
|
|
|
13）Takahashi E, Kataoka K, Fujii K, et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 2010; 12: 778-83
|
|
|
|
|
|
14）Takahashi E, Kataoka K, Indalao IL, et al. Oral clarithromycin enhances airway immunoglobulin A (IgA） immunity through induction of IgA class switching recombination and B-cell-activating gactor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol. 2012; 86: 10924-34
|
|
|
|
|
|
15）Shinahara W, Takahashi E, Sawabuchi T, et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: A retrospective analysis. PLoS One. 2013; 8: e70060
|
|
|
|
|